Corient Private Wealth
RPRX icon

Corient Private Wealth’s Royalty Pharma RPRX Stock Holding History

Corient Private Wealth’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.21M Sell
92,924
-23,453
-20% -$1.22M 0.01% 882
2026
Q1 		$3.48M Sell
116,377
-4,291
-4% -$188K 0.01% 984
2025
Q4 		$4.66M Sell
120,668
-1,488
-1% -$56.7K 0.01% 797
2025
Q3 		$4.31M Buy
122,156
+49,754
+69% +$1.8M 0.01% 760
2025
Q2 		$2.61M Sell
72,402
-4,510
-6% -$149K ﹤0.01% 922
2025
Q1 		$2.39M Buy
76,912
+30,663
+66% +$972K ﹤0.01% 913
2024
Q4 		$1.18M Buy
46,249
+21,383
+86% +$567K ﹤0.01% 1243
2024
Q3 		$703K Sell
24,866
-1,982
-7% -$54.9K ﹤0.01% 1569
2024
Q2 		$708K Buy
26,848
+214
+0.8% +$5.93K ﹤0.01% 1468
2024
Q1 		$809K Buy
26,634
+5,288
+25% +$156K ﹤0.01% 1388
2023
Q4 		$600K Buy
+21,346
New +$587K ﹤0.01% 1521
2023
Q2 		– Sell
-6,275
Closed -$226K – 2153
2023
Q1 		$226K Buy
+6,275
New +$233K ﹤0.01% 1743

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Corient Private Wealth's RPRX Position: Q2 2026 in Review

Corient Private Wealth reduced its Royalty Pharma (RPRX) stake by 20% in Q2 2026, selling an estimated $1.22M and leaving 92,924 shares worth $5.21M. The position accounts for 0.01% of the portfolio, ranked #882.

Corient Private Wealth first reported a position in RPRX in Q1 2023 and has held it in 12 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Corient Private Wealth held 92,924 shares of Royalty Pharma worth $5.21M as of Q2 2026.
  • Corient Private Wealth sold 23,453 Royalty Pharma shares in Q2 2026, an estimated $1.22M.
  • Royalty Pharma made up 0.01% of Corient Private Wealth's portfolio in Q2 2026, its #882 holding.
  • Corient Private Wealth first reported a position in Royalty Pharma in Q1 2023 and has held it in 12 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.